The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have little or no cross-resistance to either Taxol or Vinblastine. The results demonstrated that compounds disclosed herein possess potent antitumor therapeutic efficacy and are expected to have potential for clinical applications.
本公开涉及一系列8H-3a-氮杂环五环[1]
吲哚-1-基和5,10-二氢
吡咯并[1,2-b]
异喹啉衍
生物的双(羟甲基)和其双(
氨基甲酸酯) (公式I-公式IV),作为DNA二烷基化剂。初步的抗肿瘤研究表明,本公开的化合物在体外可能表现出强烈的细胞毒性和人类肿瘤异种移植物的抗肿瘤治疗效果,并且可能没有对
紫杉醇或
长春新碱的交叉耐药性。结果表明,本公开的化合物具有强大的抗肿瘤治疗效果,并有望在临床应用中发挥潜力。